Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CpG 1018-adjuvanted plague vaccine
- Development stage
- Unknown
- Lead developer
- Dynavax Technologies
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
CpG 1018-adjuvanted plague vaccine is a recombinant protein subunit vaccine candidate being developed by Dynavax in collaboration with the U.S. Department of Defense (DoD). The vaccine is designed to provide protection against plague, a severe infectious disease caused by the bacterium *Yersinia pestis*. It combines a recombinant F1-V (rF1V) fusion protein antigen with Dynavax's proprietary CpG 1018 adjuvant. CpG 1018 is a Toll-like receptor 9 (TLR9) agonist that enhances the immune response by mimicking bacterial DNA, thereby stimulating both innate and adaptive immunity. The program is currently in Phase 2 clinical development, aimed at providing a more effective and stable alternative to older plague vaccines for military and public health preparedness.
- Other names
- CpG 1018-adjuvanted plague vaccineCpG1018-adjuvanted plague vaccineCpG-1018-adjuvanted plague vaccineCpG 1018-adjuvanted vaccine for plagueCpG1018-adjuvanted vaccine for plagueCpG-1018-adjuvanted vaccine for plaguerF1V/CpG 1018 plague vaccine
02
Targets
F1 antigen (F1 capsular antigen)TLR9 (Toll-like receptor 9)LcrV (V antigen)
Beyond the preview
Go deeper on CpG 1018-adjuvanted plague vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CpG 1018-adjuvanted plague vaccine.